Article Versions Notes

Tsao C-C, Wu H-H, Wang Y-F, Shen P-C, Wu W-T, Chen H-Y, Dai Y-H. Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. Biomedicines. 2022; 10(7):1539. https://doi.org/10.3390/biomedicines10071539

Tsao, Chih-Cheng, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, and Yang-Hong Dai. 2022. "Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer" Biomedicines 10, no. 7: 1539. https://doi.org/10.3390/biomedicines10071539

Tsao, C.-C., Wu, H.-H., Wang, Y.-F., Shen, P.-C., Wu, W.-T., Chen, H.-Y., & Dai, Y.-H. (2022). Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. Biomedicines, 10(7), 1539. https://doi.org/10.3390/biomedicines10071539